Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin

William M. Miller; Clinton A. Medbery; Daniel L. Clarke-Pearson; Alan F. Barker; Russell Hull; Terry Delmore; Edward Genton; Jack Hirsh; Michael Gent; David Sackett; Dermot Mcloughlin; Peter Armstrong

doi:10.1056/NEJM198003273021316

Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin

William M. Miller, Clinton A. Medbery, Daniel L. Clarke-Pearson, Alan F. Barker, Russell Hull, Terry Delmore, Edward Genton, Jack Hirsh, Michael Gent, David Sackett, Dermot Mcloughlin, Peter Armstrong

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

To the Editor: The article by Hull and his colleagues¹ presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.² As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.³ Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,⁴ it seems logical to assume that the. No extract is available for articles shorter than 400 words.

Original language	English (US)
Pages (from-to)	752-753
Number of pages	2
Journal	New England Journal of Medicine
Volume	302
Issue number	13
DOIs	https://doi.org/10.1056/NEJM198003273021316
State	Published - Mar 27 1980

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM198003273021316

Cite this

@article{c328692163c148f9b3fce4ceac64c565,

title = "Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin",

abstract = "To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.",

author = "Miller, {William M.} and Medbery, {Clinton A.} and Clarke-Pearson, {Daniel L.} and Barker, {Alan F.} and Russell Hull and Terry Delmore and Edward Genton and Jack Hirsh and Michael Gent and David Sackett and Dermot Mcloughlin and Peter Armstrong",

year = "1980",

month = mar,

day = "27",

doi = "10.1056/NEJM198003273021316",

language = "English (US)",

volume = "302",

pages = "752--753",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "13",

}

TY - JOUR

T1 - Prevention of Recurrent Venous Thrombosis

T2 - Warfarin versus Heparin

AU - Miller, William M.

AU - Medbery, Clinton A.

AU - Clarke-Pearson, Daniel L.

AU - Barker, Alan F.

AU - Hull, Russell

AU - Delmore, Terry

AU - Genton, Edward

AU - Hirsh, Jack

AU - Gent, Michael

AU - Sackett, David

AU - Mcloughlin, Dermot

AU - Armstrong, Peter

PY - 1980/3/27

Y1 - 1980/3/27

N2 - To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

AB - To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

UR - http://www.scopus.com/inward/record.url?scp=1642527277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642527277&partnerID=8YFLogxK

U2 - 10.1056/NEJM198003273021316

DO - 10.1056/NEJM198003273021316

M3 - Letter

C2 - 7354791

AN - SCOPUS:1642527277

SN - 0028-4793

VL - 302

SP - 752

EP - 753

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 13

ER -

Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this